Aligos Therapeutics logo
Aligos Therapeutics ALGS
$ 39.7 3.52%

Quarterly report 2024-Q3
added 11-06-2024

report update icon

Aligos Therapeutics Income Statement 2011-2024 | ALGS

Annual Income Statement Aligos Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

55.9 M 55.1 M 473 M 1.04 B - - - - - - - - -

Shares

64.3 M 42.7 M 39.9 M 36.9 M - - - - - - - - -

Historical Prices

0.87 1.29 11.9 27.6 - - - - - - - - -

Net Income

-87.7 M -96 M -128 M -109 M -52.3 M -13.9 M - - - - - - -

Revenue

6.19 M - - -10.5 M - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - -

Gross Profit

- - - -10.5 M - - - - - - - - -

Operating Income

-88.1 M -97.6 M -128 M -97.8 M -54 M - - - - - - - -

Interest Expense

4.3 M 1.5 M - - - - - - - - - - -

EBITDA

-86.6 M -95.3 M -125 M -94.5 M -51.7 M -12.4 M - - - - - - -

Operating Expenses

104 M 111 M 133 M 97.8 M 54 M 13.7 M - - - - - - -

General and Administrative Expenses

30.6 M 26.4 M 28.5 M 17.9 M 10 M 3.2 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Aligos Therapeutics

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

6.27 M 156 M 156 M 3 M 1.74 M 43.2 M 42.9 M 42.9 M 42.8 M 42.7 M 42.5 M 42.7 M 42.4 M 37.6 M 37.4 M 38.1 M 3.03 M 2.81 M 2.65 M 3.93 M 2.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-19.3 M 5.06 M -34.9 M - -18 M -18.8 M -23 M - -18.6 M -19.9 M -35.6 M - -33.1 M -29.8 M -27.7 M - -33.3 M -20.8 M -20 M - -14.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

1.25 M 1.06 M 694 K - 1.08 M 4.29 M 140 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-20.1 M -26.4 M -22 M - -19.1 M -19.1 M -23.9 M - -18.9 M -20.4 M -35.6 M - -33.1 M -29.6 M -27.7 M - -21.6 M -21.3 M -20.7 M - -14.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

500 K 300 K 600 K - 1 M 1 M 700 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-19.8 M -26.1 M -21.8 M - -18.8 M -18.7 M -23.5 M - -18.4 M -19.8 M -34.9 M - -32.3 M -28.8 M -27 M - -20.8 M -20.6 M -20.4 M - -14.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

21.4 M 27.5 M 23 M - 22.3 M 26 M 26.6 M - 23.1 M 24.1 M 38.1 M - 34.6 M 31.1 M 28.6 M - 21.6 M 21.3 M 20.7 M - 14.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.63 M 6.38 M 6.67 M - 6.44 M 9.25 M 8.51 M - 5.26 M 7.58 M 6.45 M - 6.47 M 6.56 M 5.78 M - 4.22 M 4.1 M 3.42 M - 2.78 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency